The evidence base for many neurosurgical procedures has been limited. We performed a comprehensive and systematic analysis of study design, quality of reporting, and trial results of neurosurgical randomized controlled trials (RCTs). OBJECTIVE: To systematically assess the design and quality characteristics of neurosurgical RCTs. METHODS: From January 1961 to June 2016, RCTs with >5 patients assessing any 1 neurosurgical procedure against another procedure, nonsurgical treatment, or no treatment were retrieved from MEDLINE, Scopus, and Cochrane Library.
H igh-quality randomized controlled trials (RCTs) are critical to objectively evaluate the overall effectiveness of an intervention. However, RCTs represent a small proportion of the neurosurgical evidence base [1] [2] [3] and the quality of these RCTs has been shown to be suboptimal. [4] [5] [6] It is understood that the design of surgical RCTs poses unique challenges, 6, 7 but many concerns about the quality of surgical trials are often readily addressable. Examples of flaws in neurosurgical RCTs include lack of masking and allocation concealment, no justification of sample size, and incomplete subject followup. 6, 8, 9 These problems may introduce bias and can inflate the reported estimates of treatment efficacy. 10, 11 Given that RCTs constitute the evidence base on which therapeutic decision making is based, a careful assessment of trial design and reported quality, as well as changes over time, is needed.
Vranos et al 4 conducted a systematic appraisal of neurosurgical RCTs published from 1961 to 2002 and concluded that larger, more adequately powered, and more accurately reported trials are needed. We applied the same methods used in that study, but assessed trials from 2003 to 2016 to provide a current and longitudinal assessment of published neurosurgical RCTs. We evaluated trial characteristics to determine study design, quality of reporting, and trial results. Lastly, we examined trends in trial characteristics over time from 1961 to 2016 to investigate changes in the reported quality of neurosurgical trials.
METHODS Eligibility Criteria and Identification of Studies
In order to accurately assess ongoing trends in neurosurgical RCTs and to maintain consistency and comparability with previous efforts, we applied the same inclusion and exclusion criteria developed by Vranos et al. 4 To summarize, we selected RCTs analyzing neurosurgical procedures utilized in mainstream cranial and spinal neurosurgical practice, excluding trials of peripheral nerve procedures. We included RCTs that compared 1 neurosurgical procedure with another neurosurgical procedure, nonsurgical treatment, or no treatment. We excluded studies with <5 patients in each arm and studies that compared drugs, physical therapy, or conventional radiotherapy alone (Figure, Supplemental Digital Content 1). We maintained the exclusion strategy of Vranos et al, 4 excluding trials where most procedures are generally performed by non-neurosurgeons. The pertinence of procedures to general neurosurgical practice was judged by 2 board-certified neurosurgeons. Studies with multiple duplicate publications of the same trial were screened and the report with the lengthiest follow-up was retained.
Systematic Review and Search Strategy
We obtained the search strategy utilized by Vranos et al 4 and applied it to the same databases, MEDLINE (January 2003-July 2016), Scopus (January 2003-July 2016, which indexes all the content in EMBASE), and the Cochrane Library Controlled Trials Registry. The search strategy and review protocol are provided in Supplemental Digital Content 2. We retrieved all publications in English, after confirming that nonEnglish publications constituted a small fraction (2/108) of the trials included in the 2004 study by Vranos et al. 4 Meeting proceedings were excluded because these unpublished trials could not be appropriately evaluated through the limited information available in the abstract. Studies were screened for inclusion independently by 3 authors and conflicts were resolved by consensus.
Data Extraction
Four authors extracted data, using the same methodology as Vranos et al, 4 which was implemented in prior studies as well. 12, 13 Definitions of all variables were confirmed with the senior author on the original assessment of neurosurgical RCTs. The following data were extracted from each study-the indication for procedure, study size, patient characteristics (eg, gender), acuity of the indication (ie, acute [<48 h], subacute [between 2 and 14 d], or chronic [>14 d]), followup length of the study (mean or median), publication year, location of study, number of trial centers, the anatomic location of the indication, and funding source.
Several accepted methods to assess quality of RCTs exist. 14 We decided to maintain the methodology of Vranos et al 4 to be consistent and allow for comparison over time and extracted data commonly used as measures of reported quality. We limited our search criteria to that used in Vranos et al 4 to facilitate accurate of comparisons over time. Though the Cochrane risk of bias tool 16 was not explicitly utilized, we extracted key components of this tool (ie, randomization, allocation concealment 15 , and masking) at the study level. Given the inclusion criteria of the current study, focusing on published RCTs, publication bias was not fully evaluable. Bias across studies is characterized by descriptive statistics summarizing randomization, allocation concealment, and masking. Trial results were evaluated as showing significant difference, trend for significance, or nonsignificant difference for the intervention vs the control arm. This determination was based on an overall assessment of the key outcomes with significance of P < .05. For nonsignificant differences, trends or no difference between the arms were differentiated based on the interpretation of the abstract and the discussion of each report. We also reported whether the trial arms were equally experimental or whether a newer or novel intervention was studied against an existing one.
Statistical Analysis
Descriptive statistics are reported using mean (standard deviation) or median (interquartile range) for the design, quality, and outcome characteristics of included RCTs. Pearson's Chi-squared test was utilized for analyses of associations between funding sources and quality characteristics. Spearman correlation coefficients were used to evaluate whether quality characteristics correlated with study size and length of followup and whether study size, follow-up, and quality characteristics correlated with significant RCT outcomes. Interpretation of these exploratory correlation analyses considered Bonferroni correction for 39 correlations assessed. In addition, we assessed whether RCT characteristics evolved with time. RCTs divided into epochs that most equally distributed the total number of trials in each time period. Jonckheere's trend test 17 was used to assess significance of trends over time across time periods. All analysis was conducted in the R statistical language.
18

RESULTS
Results of Systematic Review
Our initial search strategy returned 18 461 studies eligible for title and abstract screening, of which 766 progressed to fulltext screening. Studies were excluded for duplication (n = 3482) and for not meeting study inclusion criteria (n = 14 578); eg, lack of randomization, language restriction, multiple reports of a single trial. These decisions for exclusion are depicted in , and Neurosurgery (4.2%, n = 17). A total of 38.9% of trials were associated with disc disease, 14.5% with "other" spinal indications (eg, spinal stenosis or osteoporotic vertebral fracture), 11.0% associated with functional neurosurgical conditions (eg, Parkinson's disease), 11.0% associated with trauma, 9.8% associated with cerebrovascular conditions, 6.2% associated with spondylolisthesis, 4.0% associated with tumor, 2.2% associated with hydrocephalus, 1.5% of RCTs were conducted for congenital conditions, and 1.3% were associated with other cranial conditions (eg, cranioplasty). .
FIGURE 1. Neurosurgical RCTs have increased markedly over time
Design Characteristics of Neurosurgical RCTs
The median sample size was 73 patients (interquartile range [IQR], 43-157.25). The majority of trials were for chronic diseases (82.5%) with median follow-up of 24 mo (IQR, 12-36). More than one-third of the trials were multicenter trials, with most multicenter trials involving spinal RCTs (62.6%). Most RCTs (75.8%) compared a surgical procedure against another surgical or minimally invasive procedure, 19.3% of trials utilized a nonsurgical comparator, and 5% of RCTs compared a surgical procedure to a placebo or sham treatment. A total of 33.8% of trials reported having received no funding, 21.9% were supported by industry, 16.9% of trials failed to mention any funding source, 12.7% of trials reported government funding, 8.2% reported mixed funding sources (eg, private and government funding), 4.5% of RCTs reported private foundation, and 2.0% were supported by a professional organization ( Table 1) .
Quality of Reporting
The overwhelming majority of trials reported inclusion and exclusion criteria (92.3%), specified sample size in each arm (99.0%), and reported baseline characteristics (88.5%). Less than 4% of trials reported a statistically significant difference in baseline characteristics between the arms. Most trials (65.1%) specified the mode of randomization, but only 28.9% detailed allocation concealment. We identified 52 (13.0%) double-blind RCTs, 90 (22.4%) single-blind, and 259 (64.6%) open-label trials. Withdrawals were described in 60.6% of trials and power calculations were described in 142 (35.4%) of trials. Power was ≥80% at alpha = 0.05 in most trials (120 of 142) which specified power calculations. One hundred seventy-three trials (43.1%) reported significant efficacy, 166 (41.4%) trials reported no difference in outcomes, 53 (13.2%) claimed a trend for efficacy, and 9 (2.24%) trials reported significant harm ( Table 2) .
Influence of Funding Source
Government funding did not correlate with significant efficacy of trial outcome (P = .29), but there was a trend toward association with superior study quality, particularly reporting of power calculations (P = .008), and of allocation concealment (P = .026). We observed a similar pattern in studies which reported receiving no funding, no association with significant findings (P = 1.0), and significant associations with reporting power calculations (P = .007) and allocation concealment (P = .007). Notably, studies with industry funding were more likely to report significant efficacy (P = .02), but were not associated with reporting of power calculations (P = .27) or allocation concealment (P = .42).
Correlations Between Quality Factors and RCT Size, Length of Follow-up, and Significant Outcome
We found that larger RCTs were more likely to specify randomization and allocation concealment (P = .0001 and .00003, respectively), have a double-blind design (P = .003, not statistically significant after Bonferroni correction for the 39 correlations assessed), describe withdrawals (P = .0005), denote power calculations (P = .001), and possibly have well-specified primary outcomes (P = .004, not significant after Bonferroni correction). We also found that larger trials were possibly less likely to compare equally experimental procedures (P = .004, not significant after Bonferroni correction). Procedures were denoted to be equally experimental procedures if neither was considered superior therapy than the other (ie, if one of the procedures was not the gold standard and/or one of the procedures had more favorable scientific evidence about its use). RCTs with longer median follow-up were possibly less likely to specify randomization mode (P = .005, not significant after Bonferroni correction; P = .105; Table 3 ).
Changes in Neurosurgical RCTs Over Time
We were able to assess trends in neurosurgical trials from 1961 to 2016 by using the same search strategy, inclusion/exclusion criteria, and variable definitions as Vranos et al. 4 We found statistically significant trends in the total number of trials (P < .001) as well as the percentage of trials mentioning funding source Formally statistically significant correlations (P < .0013) are italicized.
(P < .001), describing power calculations (P = .017), presenting well-specified primary outcomes (P = .049), and trials with results showing a trend for efficacy (P = .005; Table 4 ). All these features were increasing over time, with the exception of results showing a trend for efficacy, which was observed to decrease over time.
DISCUSSION
Summary of Findings
We conducted a systematic appraisal of the reported design and quality of neurosurgical RCTs and identified 401 published trials on brain and spine conditions treated by neurosurgeons over the .017
Primary outcomes well specified .005
Formally statistically significant correlations (P < .05) are italicized.
last 13 yr. Although the number of published studies in neurosurgery has increased significantly, the overall number of neurosurgical RCTs remains low. This increase in number of published trials parallels overall trends in the neurosurgical literature. 19 The most common surgical problem that the RCTs examine has not changed over time, with roughly 40% focused on disc disease. Disc disease continues to dominate the field. Disc disease and other spinal problems are more likely to be chronic and lend themselves toward RCT design in the multicenter setting because of the high percentages of follow-up. Consequently, almost twothirds of all multicenter RCTs are related to spinal procedures. However, RCTs on nearly all other neurosurgical problems have increased since the last report in 2004 reflecting the expanding interest emerging fields such as functional neurosurgery.
Historically, quality of neurosurgical RCTs tends to be suboptimal, as the studies are small and underpowered. 5, 6 Although the field has not been completely remedied of these issues, we observed several improvements. The median sample size in all RCTs and number of multicenter trials have risen slightly since 2004. The vast majority of neurosurgical RCTs continue to report their inclusion and exclusion criteria, sample size per arm, and baseline characteristics, as they had also done in the past. Since patients that withdraw may be significantly different from those that remain, failure to report withdrawals may bias results. 17 The reporting of justification of study size has increased, which is an important improvement. Nearly twice as many studies report their power calculations since the 2004 report by Vranos et al. 4 Trials with larger samples sizes were more likely to report important study quality characteristics such as randomization mode and allocation concealment.
Most studies report statistically significant efficacy in their results. Compared to earlier trials, nearly twice as many RCTs reported significant efficacy. As noted in Vranos et al, 4 the reporting of no difference in underpowered studies leads to the improper assumption that both arms of the RCT are equally effective. However, we found that reporting statistically significant efficacy is associated with a lower likelihood of reporting power calculations. This may be an indirect sign that some of the statistically significant results may be spurious, eg, post hoc analyses.
Funding sources have been shown to influence the reporting of significant efficacy findings and a favorable interpretation in RCTs in many fields. 20 We found that reporting of funding resources has dramatically improved in neurosurgery RCTs over time. Government funding was not statistically shown to increase the reporting of significant results, but did lead to a significant higher likelihood of the reporting power calculations and allocation concealment, 2 features that suggest higher transparency and/or more careful design. Notably, industry-supported trials were associated with substantial increases in the proportion of statistically significant trial outcomes, although they were not more likely to report power calculations or allocation concealment. It is difficult to distinguish if industry sponsoring may lead to selection of outcomes that are more likely to yield favorable results, publication and selective reporting bias for favorable outcomes, and/or more favorable interpretation of the data.
Relation to RCTs in Other Surgical Fields
Previous studies in other surgical disciplines have suggested that the design and reporting of surgical RCTs would benefit from improvement. Banglawala et al 21 studied RCTs in otolaryngology and found that randomized trials remain rare in this field. Similar to our findings in neurosurgery, they observed suboptimal RCT design and reporting. 21 Voineskos et al 22 reviewed 173 plastic surgery RCTs and found that proper randomization was described in 35%, allocation concealment in 12%, and primary outcomes in 34% of trials. In general surgery, studies have consistently identified suboptimal quality of reporting RCTs. 23, 24 Though direct comparisons of medical and surgical trials are uncommon, Boutron et al 25 compared nonpharmacological (34% surgical interventions) and pharmacological trials for treatment of hip and knee osteoarthritis. This study found that pharmacological trials had significantly better quality scores, though certain flaws were observed in both types of RCTs (eg, lack of intention-to-treat analyses).
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Implications for Clinical Science in Neurosurgery
While systematic assessments of clinical research in neurosurgery are limited, several groups have made important contributions. Rothoerl et al 3 called for the increase in number of RCTs in 2003, as these studies have a greater influence than case reports that still dominate the field with their large numbers of publications. Similarly, Yarascavitch et al 1 pointed out the lack of level I and II evidence in neurosurgery journals. Kiehna et al 5 have suggested that an improved awareness of CONSORT guidelines by all neurosurgery stakeholders may lead to improved trial design and reporting. Mansouri et al 6 argue that in some cases it is not feasible to design a neurosurgical trial that meets the guidelines of the prototypical RCT, and thus some questions in our field must be interrogated using alternative research designs.
While we believe that there are clinical questions in neurosurgery that require alternative research designs, we maintain that it is critical to improve RCTs in neurosurgery. Improvements may pertain to the design, conduct, reporting, and transparent communication and interpretation of clinical research. While it is reassuring that the number of RCTs done per year has increased over time, it is important also to increase the sample size and power of these trials. Wider adoption of multicenter trials could achieve this goal. Improvements at the design and conduct level can focus on making allocation concealment and masking more prevalent. Thorough registration of trial information and upfront availability of the full trial protocols is also important in ensuring the proper reporting of essential aspects of the trial design, conduct, and analysis in the literature. 26 Notably, a later assessment found that higher quality publications increased, in both number and proportion, both in JBJS, as well as in other orthopedics journals, 27 although a causeand-effect relationship cannot be proven. The Journal of Neurosurgery has recently begun a similar level-of-evidence reporting for some clinical articles. 28 The main neurosurgery journals could help achieve improvements in the field by requiring not only cursory registration of trials, but also availability of full protocols, and by insisting on capturing in the published papers information that is essential for understanding how a trial was designed, run, and analyzed.
Limitations
An inherent limitation in our study is the inability to capture articles that were not reported in databases we used. Furthermore, although we were comprehensive in our search criteria, we excluded trials without a surgical arm, which may have excluded trials of neurosurgical patients and/or neurosurgical investigators, and did not include procedures performed primarily by nonneurosurgeons (eg, carotid endarterectomy). Neurosurgeons treat a variety of conditions, and we implemented these eligibility criteria to specifically assess the core type of surgical trials, which have been shown to have design and implementation issues that are unique and different from nonsurgical RCTs. We also wanted to be as consistent with the earlier publication by one of the senior authors on this topic since we used the same methodology to allow for comparisons over time. 4 Finally, we should acknowledge that our evaluation captured the reported information and this may not always be an accurate representation of the study design and conduct. For example, improvement in reporting of allocation concealment may mean that more recent trials were more likely to use allocation concealment and/or more likely to be sensitized that is important to report that they did use allocation concealment.
CONCLUSION
Our results indicate that neurosurgical RCTs have improved in several reported quality measures, but that further improvement is necessary. Our longitudinal analysis of neurosurgical RCTs reaffirms the shortcomings elaborated in previous reports, but also demonstrates that progress has been made. RCTs that are conducted in neurosurgery must be held to a high standard to enable the development of a robust and reproducible evidence base for clinicians and patients.
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